title: Glycerol enhances CDDP-induced growth inhibition of thyroid anaplastic carcinoma tumor carrying mutated p53 gene.
abstract: To increase the chemo-sensitivity of anaplastic thyroid carcinoma, we examined the effects of glycerol on the tumor growth after CDDP treatment. The cultured cells of an anaplastic thyroid carcinoma cell line (8305c) carrying a mutated p53 gene (mp53) were transplanted into the thighs of nude mice. Tumor growth was evaluated until 24 days after intraperitoneal injection of CDDP and/or pre-injection of glycerol to the tumor. We treated the mice with half the tumor volume of glycerol (1.2 M) and/or CDDP at 6 mg/kg (BW) either of which hardly inhibited tumor growth by itself. When we treated the mice with the combination of glycerol and CDDP at these concentrations, however, a clear delay of the tumor growth was observed. We also immunohistochemically analyzed the effects of glycerol on the induction of caspase-3 activity and apoptosis. Cells positive for cleavage to active caspase-3 and 85 kDa PARP, and apoptosis were hardly observed in the tumors when they were treated with glycerol or CDDP alone. In contrast, when they were treated with CDDP combined with glycerol, such positive cells were significantly increased. It has been shown that glycerol synergistically enhanced the effects of CDDP as a tumor suppressive agent through the induction of caspase-3-mediated apoptosis in 8305c tumors. Therefore, glycerol might be useful for chemotherapy in patients with mp53 cancer cells.
authors.affiliation: Department of Otorhinolaryngology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
authors.forename: Kazue
authors.initials: K
authors.lastname: Yuki
authors.forename: Akihisa
authors.initials: A
authors.lastname: Takahashi
authors.forename: Ichiro
authors.initials: I
authors.lastname: Ota
authors.forename: Ken
authors.initials: K
authors.lastname: Ohnishi
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Yasumoto
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Kanata
authors.forename: Katsunari
authors.initials: K
authors.lastname: Yane
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hosoi
authors.forename: Takeo
authors.initials: T
authors.lastname: Ohnishi
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002277:Carcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D018929:Cell Culture Techniques; D002945:Cisplatin / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D004357:Drug Synergism; D016158:Genes, p53 / Q000235:genetics; D005990:Glycerol / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D023421:Models, Animal; D009368:Neoplasm Transplantation; D017354:Point Mutation / Q000235:genetics; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
chemical_list: C505407:CASP3 protein, human; C505409:Casp3 protein, mouse; D053148:Caspase 3; D020169:Caspases; D005990:Glycerol; D002945:Cisplatin